Summary

Middle East Pharmaceutical Contract Development & Manufacturing Organization Market Summary

The Middle East pharmaceutical contract development and manufacturing organization market size was estimated at USD 3.50 billion in 2024 and is projected to reach USD 5.39 billion by 2033, growing at a CAGR of 4.90% from 2025 to 2033. The market growth is driven by increasing healthcare spending, rising prevalence of chronic diseases, and a growing demand for cost-effective drug development and manufacturing facilities.

In addition, growing government investments in healthcare infrastructure and the presence of strategic locations in the Middle East as a trade hub that connects Asia, Europe, and Africa have further contributed to market growth. Moreover, most of the established pharmaceutical companies across the globe are expanding operations in the Gulf and broader Middle East with the shifting trends of outsourcing towards contract development & manufacturing organization (CDMO) to optimize costs, accelerate time-to-market, and enhance supply chain resilience.

Moreover, rising technological advancements are enhancing both efficiency & quality within pharmaceutical development and manufacturing is expected to drive the market. Besides, the integration of automation, digital platforms, and advanced analytical tools has streamlined operations further, minimizing errors. For instance, processes such as continuous manufacturing and single-use technologies are increasingly used to shorten production timelines and provide flexibility for both small and large molecule products. In addition, data-driven monitoring systems & real-time analytics have been implemented to ensure greater precision, compliance, and productivity across the entire value chain. Furthermore, in the Middle East, pharmaceutical innovation is driven by an expanding pipeline of biologics, biosimilars, and specialty medicines. CDMOs are stepping up to offer their expertise in complex formulations, sterile manufacturing, and the production of HPAPIs.

In addition, growing collaborative partnerships among global and emerging market players are expected to enhance the capabilities in the Middle East for biologics, cell and gene therapies, and specialized therapeutic areas. In addition, the growing expansion of R&D activities in the region and increasing requirement for outsourcing facilities due to evolving demands of the pharmaceutical pipeline are expected to drive the market over the estimated time period.

Also, the regulatory landscape in the region is more aligned with the international standards to attract investment and prioritize patient safety. Authorities such as the Saudi Food and Drug Authority & the UAE Ministry of Health and Prevention are further enhancing quality assurance and compliance frameworks. Besides, increasing requirements to harmonize regulatory guidelines with those from the U.S. FDA and EMA are underway to facilitate global market access for regionally manufactured drugs. Furthermore, growing approval processes and transparent regulatory pathways that are established to support CDMOs in maintaining competitiveness and building credibility within global pharmaceutical supply chains are expected to drive the market over the estimated time period.

Middle East Pharmaceutical Contract Development And Manufacturing Organization Market Report Segmentation

This report forecasts revenue growth at the regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Middle East pharmaceutical contract development and manufacturing organization market report based on type, product, service, workflow, therapeutic area, end use, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Small Molecule
o Branded
o Generic
• Large Molecule
o Biologics
o Biosimilar
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• API
o Traditional Active Pharmaceutical Ingredient (Traditional API)
o Highly Potent Active Pharmaceutical Ingredient (HP-API)
o Biologics
o Others
• Drug Product
o Oral solid dose
o Semi-solid dose
o Liquid dose
o Others
• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Contract Development
o Pre-formulation & Formulation Development Service
o Process Development & Optimization
o Analytical Testing & Method Validation
o Scale-up & Tech Transfer
• Contract Manufacturing
o API Manufacturing
o Finished Drug Products Manufacturing
• Packaging and Labelling
• Regulatory Affairs
• Others
• Workflow Outlook (Revenue, USD Million, 2021 - 2033)
• Clinical
• Commercial
• Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Infectious Diseases
• Neurological Disorders
• Cardiovascular Disease
• Metabolic Disorders
• Autoimmune Diseases
• Respiratory Diseases
• Ophthalmology
• Gastrointestinal Disorders
• Orthopedic Diseases
• Dental Diseases
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Small Pharmaceutical Companies
• Medium Pharmaceutical Companies
• Large Pharmaceutical Companies
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• Middle East
o UAE
o Saudi Arabia
o Kuwait
o Qatar
o Oman

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Product
1.2.3. Service
1.2.4. Workflow
1.2.5. Therapeutic Area
1.2.6. End Use
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.7.2. Top-Down Analysis
1.7.3. Bottom-Up Approach
1.7.4. Multivariate Analysis
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Middle East Pharmaceutical Contract Development and Manufacturing Organization Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.2.3. Market Opportunity Analysis
3.3. Industry Ecosystem Analysis
3.3.1. Demand Analysis
3.3.2. Supply Chain Analysis
3.4. Technology Landscape
3.5. Clinical Trial Volume Analysis, 2024
3.6. Pricing Analysis
3.7. Tariff and Trade Agreement Impact Analysis
3.8. Value Chain Analysis
3.8.1. Supply Trends
3.8.2. Demand Trends
3.9. Market Analysis Tools
3.9.1. Porter’s Five Force Analysis
3.9.2. PESTEL by SWOT Analysis
Chapter 4. Middle East Pharmaceutical Contract Development and Manufacturing Organization Market: Type Estimates & Trend Analysis
4.1. Middle East Pharmaceutical Contract Development and Manufacturing Organization Market, By Type: Segment Dashboard
4.2. Middle East Pharmaceutical Contract Development and Manufacturing Organization Market, By Type: Movement Analysis
4.3. Middle East Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Type, 2021 - 2033 (USD Million)
4.4. Small Molecule
4.4.1. Small Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.2. Branded
4.4.2.1. Branded Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.3. Generic
4.4.3.1. Generic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Large Molecule
4.5.1. Large Molecule Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.2. Biologics
4.5.2.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.3. Biosimilar
4.5.3.1. Biosimilar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Middle East Pharmaceutical Contract Development and Manufacturing Organization Market: Product Estimates & Trend Analysis
5.1. Middle East Pharmaceutical Contract Development and Manufacturing Organization Market, By Product: Segment Dashboard
5.2. Middle East Pharmaceutical Contract Development and Manufacturing Organization Market, By Product: Movement Analysis
5.3. Middle East Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Product, 2021 - 2033 (USD Million)
5.4. API
5.4.1. API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.2. Traditional Active Pharmaceutical Ingredient (Traditional API)
5.4.2.1. Traditional Active Pharmaceutical Ingredient (Traditional API) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.3. Highly Potent Active Pharmaceutical Ingredient (HP-API)
5.4.3.1. Highly Potent Active Pharmaceutical Ingredient (HP-API) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.4. Biologics
5.4.4.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.5. Others
5.4.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Drug Product
5.5.1. Drug Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5.2. Oral Solid Dose
5.5.2.1. Oral Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5.3. Semi-Solid Dose
5.5.3.1. Semi-Solid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5.4. Liquid Dose
5.5.4.1. Liquid Dose Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5.5. Others
5.5.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Middle East Pharmaceutical Contract Development and Manufacturing Organization Market: Service Estimates & Trend Analysis
6.1. Middle East Pharmaceutical Contract Development and Manufacturing Organization Market, By Service: Segment Dashboard
6.2. Middle East Pharmaceutical Contract Development and Manufacturing Organization Market, By Service: Movement Analysis
6.3. Middle East Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
6.4. Contract Development
6.4.1. Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.2. Pre-formulation & Formulation Development Service
6.4.2.1. Pre-formulation & Formulation Development Service Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.3. Process Development & Optimization
6.4.3.1. Process Development & Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.4. Analytical Testing & Method Validation
6.4.4.1. Analytical Testing & Method Validation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.5. Scale-up & Tech Transfer
6.4.5.1. Scale-up & Tech Transfer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Contract Manufacturing
6.5.1. Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.2. API Manufacturing
6.5.2.1. API Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.3. Finished Drug Products Manufacturing
6.5.3.1. Finished Drug Products Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Packaging and Labelling
6.6.1. Packaging and Labelling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Regulatory Affairs
6.7.1. Regulatory Affairs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Others
6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Middle East Pharmaceutical Contract Development and Manufacturing Organization Market: Workflow Estimates & Trend Analysis
7.1. Middle East Pharmaceutical Contract Development and Manufacturing Organization Market, By Workflow: Segment Dashboard
7.2. Middle East Pharmaceutical Contract Development and Manufacturing Organization Market, By Workflow: Movement Analysis
7.3. Middle East Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Workflow, 2021 - 2033 (USD Million)
7.4. Clinical
7.4.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Commercial
7.5.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Middle East Pharmaceutical Contract Development and Manufacturing Organization Market: Therapeutic Area Estimates & Trend Analysis
8.1. Middle East Pharmaceutical Contract Development and Manufacturing Organization Market, By Therapeutic Area: Segment Dashboard
8.2. Middle East Pharmaceutical Contract Development and Manufacturing Organization Market, By Therapeutic Area: Movement Analysis
8.3. Middle East Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By Therapeutic Area, 2021 - 2033 (USD Million)
8.4. Oncology
8.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Infectious Diseases
8.5.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Neurological Disorders
8.6.1. Neurological Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7. Cardiovascular Diseases
8.7.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8. Metabolic Disorders
8.8.1. Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.9. Autoimmune Diseases
8.9.1. Autoimmune Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.10. Respiratory Diseases
8.10.1. Respiratory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.11. Ophthalmology
8.11.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.12. Gastrointestinal Disorders
8.12.1. Gastrointestinal Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.13. Orthopedic Diseases
8.13.1. Orthopedic Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.14. Dental Diseases
8.14.1. Dental Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.15. Others
8.15.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Middle East Pharmaceutical Contract Development and Manufacturing Organization Market: End Use Estimates & Trend Analysis
9.1. Middle East Pharmaceutical Contract Development and Manufacturing Organization Market, By End Use: Segment Dashboard
9.2. Middle East Pharmaceutical Contract Development and Manufacturing Organization Market, By End Use: Movement Analysis
9.3. Middle East Pharmaceutical Contract Development and Manufacturing Organization Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
9.4. Small Pharmaceutical Companies
9.4.1. Small Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.5. Medium Pharmaceutical Companies
9.5.1. Medium Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.6. Large Pharmaceutical Companies
9.6.1. Large Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 10. Middle East Pharmaceutical Contract Development And Manufacturing Organization Market: Regional Estimates & Trend Analysis
10.1. Regional Market Dashboard
10.2. Regional Market Share Analysis, 2024 & 2033
10.3. Middle East
10.3.1. Middle East Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.3.2. UAE
10.3.2.1. Key Country Dynamics
10.3.2.2. Competitive Scenario
10.3.2.3. Regulatory Framework
10.3.2.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.3.3. Saudi Arabia
10.3.3.1. Key Country Dynamics
10.3.3.2. Competitive Scenario
10.3.3.3. Regulatory Framework
10.3.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.3.4. Kuwait
10.3.4.1. Key Country Dynamics
10.3.4.2. Competitive Scenario
10.3.4.3. Regulatory Framework
10.3.4.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.3.5. Qatar
10.3.5.1. Key Country Dynamics
10.3.5.2. Competitive Scenario
10.3.5.3. Regulatory Framework
10.3.5.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
10.3.6. Oman
10.3.6.1. Key Country Dynamics
10.3.6.2. Competitive Scenario
10.3.6.3. Regulatory Framework
10.3.6.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 11. Competitive Landscape
11.1. Key Participant Categorization
11.1.1. Market Leaders
11.1.2. Emerging Players
11.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
11.3. Company Profiles
11.3.1. Thermo Fisher Scientific
11.3.1.1. Company Overview
11.3.1.2. Financial Performance
11.3.1.3. Service Benchmarking
11.3.1.4. Strategic Initiatives
11.3.2. Eurofins CDMO
11.3.2.1. Company Overview
11.3.2.2. Financial Performance
11.3.2.3. Service Benchmarking
11.3.2.4. Strategic Initiatives
11.3.3. Piramal Pharma Solutions
11.3.3.1. Company Overview
11.3.3.2. Financial Performance
11.3.3.3. Service Benchmarking
11.3.3.4. Strategic Initiatives
11.3.4. Lonza
11.3.4.1. Company Overview
11.3.4.2. Financial Performance
11.3.4.3. Service Benchmarking
11.3.4.4. Strategic Initiatives
11.3.5. Recipharm AB
11.3.5.1. Company Overview
11.3.5.2. Financial Performance
11.3.5.3. Service Benchmarking
11.3.5.4. Strategic Initiatives
11.3.6. Catalent, Inc.
11.3.6.1. Company Overview
11.3.6.2. Financial Performance
11.3.6.3. Service Benchmarking
11.3.6.4. Strategic Initiatives
11.3.7. WuXi AppTec, Inc.
11.3.7.1. Company Overview
11.3.7.2. Financial Performance
11.3.7.3. Service Benchmarking
11.3.7.4. Strategic Initiatives
11.3.8. Samsung Biologics
11.3.8.1. Company Overview
11.3.8.2. Financial Performance
11.3.8.3. Service Benchmarking
11.3.8.4. Strategic Initiatives
11.3.9. Siegfried Holding AG
11.3.9.1. Company Overview
11.3.9.2. Financial Performance
11.3.9.3. Service Benchmarking
11.3.9.4. Strategic Initiatives
11.3.10. Corden Pharma International
11.3.10.1. Company Overview
11.3.10.2. Financial Performance
11.3.10.3. Service Benchmarking
11.3.10.4. Strategic Initiatives
11.3.11. Cambrex Corporation
11.3.11.1. Company Overview
11.3.11.2. Financial Performance
11.3.11.3. Service Benchmarking
11.3.11.4. Strategic Initiatives
11.3.12. Delpharm
11.3.12.1. Company Overview
11.3.12.2. Financial Performance
11.3.12.3. Service Benchmarking
11.3.12.4. Strategic Initiatives
11.3.13. Jubilant Pharmova / HollisterStier
11.3.13.1. Company Overview
11.3.13.2. Financial Performance
11.3.13.3. Service Benchmarking
11.3.13.4. Strategic Initiatives
11.3.14. Almac Pharma Service
11.3.14.1. Company Overview
11.3.14.2. Financial Performance
11.3.14.3. Service Benchmarking
11.3.14.4. Strategic Initiatives